September to Remember (9.5.2025)

Jack Cush, MD

Sep 05, 2025 7:00 am

Dr. Jack Cush reviews the news and journal reports from RheumNow. This week - unemployment, diagnosing Sjogren's and a lot of ILD.

6 yr study of Dutch #SLE pts (n 221) - unemployment was high (54%) & increased over time. Employ ed assoc w/ supervisor support, regular working hrs, skill discretion, decision authority. Unemployment most from SLE Sxs (63%) & assoc w/ older, less education, Dz Dur, organ damage. https://buff.ly/BISnE6I
Study of 607 systemic sclerosis (SSc) pts finds Pulm arterial HTN (PAH) in 77 (12.7%). While early immunosuppression didnt reduce odds of PAH (OR 0.74, p=0.495), early mycophenolate was protective (OR 0.12; p=0.048). Only HCQ use signif. improved survival (HR 0.04; p= 0.004). https://buff.ly/4zi2ZqT
Prospective study of 171 suspected Sjogrens (130 dx w/ SjD) pts compared Dx accuracy - Labial gland Bx best Dx efficacy (AUC 0.90), followed Ro/SSA (AUC 0.79), Omeract score (AUC 0.78). Salv gland US grade 3 strongly predicted +Bx (AUC 0.77) & correlated w/ salivary flow ~-0.5 https://buff.ly/Mp1LnLX
J&J announced it has halted its combination biologic study in difficult to treat RA. Phase 2a DAISY proof-of-concept studied the combo of nipocalimab and TNFi in refractory RA, but 12 wk results failed to evidence of efficacy. https://t.co/T4n4GNqtVC
LTBI risk in rheumatic pts is high (22%). Metanalysis 18 studies, 12,167 rheum pts shows LTBI signif. incr w/ current smoking (OR 1.50), golimumab(OR 2.90), Chloroquine (OR 1.27), age >40 (OR 1.84), prior TB OR 3.26). LTBI not increased w/ RF, ADA, ETN, BCG, Pred, smoking, DM https://t.co/0PayHJqwDn
September is Pulmonary Fibrosis Awareness month. PF & ILD affect more than 250,000 Americans. The Pulmonary Fibrosis Foundation (PFF), will lead a nationwide campaign to raise awareness https://t.co/BYKeLcFP2U
JAMA Patient Information: Interstitial Lung Disease
Connective tissue disease associated with interstitial lung disease (CTD-ILD) market is estimated to be $5.8 Billion USD in 2024 and is projected to grow to 9.3 billion in 2034, driven by increase in autoimmune Dz, adoption of biologics, ongoing clinical anti-fibrotic trials https://t.co/UqshQgNOau
Retrospective Korean study of #RA & ILD pts (n 151) - ILD duration & UIP pattern significantly affected prognosis. 62% were non-smokers, DAS28=4.9, UIP in 60%. @4 years, ILD progressed in 58%; mortality=21%. MTX did not affect progression or mortality. https://t.co/1XNcWsAuea
Abatacept and Methotrexate may Lower Risk of Interstitial Lung Disease in RA
Lung Cancer in Rheumatoid Arthritis and Interstitial Lung Disease A matched cohort study from the Veterans Health Administration shows that RA patients have a >50% increased risk of lung cancer, a 3-fold higher risk of lung cancer in RA-ILD. https://t.co/Gjn2M2CNAO
Review of cancer-associated myositis (CAM) & assoc myositis-specific or myositis-associated autoantibodies. 2017 meta-analysis 5 studies & 4538 pts w/ DM or PM, the cancer risk (SIR) for DM = 4.66, but PM = 1.75. Cancer risk ^^ w/ Low serum KL-6, TIF1γ, NXP2, HMGCR Abs https://t.co/xsOt4wPIXB
GLP-1 receptor agonists use assoc w/ lower risk of uveitis compared vs controls. EHR study 258 026 ea on GLP-1RA or not. GLP-1RAs exhibited roughly half the risk of developing uveitis. Protective effect greater than that of metformin & insulin but lower than SGLT2i https://t.co/w311b6swc3
Combined Therapy in Rheumatoid Arthritis Interstitial Lung Disease
Rheumatoid Arthritis ILD Complications and management - Video by Dr. Scott Mattson
Therapeutic Update: ILD Treatment and Guidelines
Tuesday Nite Rheumatology (TNR) This week LIVE September 9th, 7PM EST Join Drs. Sindhu Johnson, Anna-Maria Hoffmann-Vold, Scott Matson & Jack Cush, as they review ACR & EULAR #ILD guidelines. And the future Rx of ILD Don’t miss it! https://t.co/PVo0dbQLCn #Rheumatology #ILD https://t.co/gp1qfeEt3S